MindMed has dosed the first subject in the Phase III Panorama study of MM120 ODT for the treatment of generalised anxiety ...

MSD said that its sotatercept steering committee called for the trial to end as patients are moved to the ongoing open-label ...

MM PD market growth will be driven by advancements in innovative therapies, including the first DMTs, and a growing patient ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.

A year after reducing half of its workforce, Allakos will downsize to just 15 employees as it halts the development of AK006.

The US Food and Drug Administration has released draft guidance on protocol deviations, but experts say it could go further.

The potential secretary for Health and Human Services has been forced to defend his previous anti-vaccine stances at his ...

Arena International’s Outsourcing in Clinical Trials West Coast 2025 will discuss patient centricity, diversity, and ...

Kashiv Biosciences has reported that a trial of its 125mg/mL pre-filled syringe injection, KSHB002, has achieved its primary ...

Velocity Clinical Research has announced a collaboration with VCT to address the challenge of double enrolment of subjects in trials, ...

Akero Therapeutics has revealed preliminary outcomes from its Phase IIb study of EFX in individuals with compensated ...

The Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance ...